Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery

Biomaterials

Volumn 35, Issue 26, 2014, Pages 7543-7552

  Kim, Hyun Ah ^a   Nam, Kihoon ^a   Kim, Sung Wan ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

Author keywords

Bio reducible polymer; Cancer gene therapy; RGD peptides; Targeted gene delivery; VEGF siRNA

Indexed keywords

AMINO ACIDS; ASSAYS; CELLS; CONJUGATED POLYMERS; DISEASES; DNA; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; MOLECULAR BIOLOGY; PEPTIDES; TUMORS;

CANCER GENE THERAPY; PHYSICAL CHARACTERIZATION; RGD PEPTIDE; TARGETED GENE DELIVERY; THERAPEUTIC EFFECTS; TRANSFECTION ASSAYS; TRANSFECTION EFFICIENCY; VEGF SIRNA;

FUNCTIONAL POLYMERS;

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; MACROGOL; PLASMID DNA; POLY(CYSTAMINE BISACRYLAMIDE DIAMINOHEXANE); POLYAMIDOAMINE; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; ARTICLE; BINDING COMPETITION; CANCER GENE THERAPY; CANCER INHIBITION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG UPTAKE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERNALIZATION; MCF 7 CELL LINE; NONVIRAL GENE DELIVERY SYSTEM; PANCREATIC CANCER CELL LINE; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; ADMINISTRATION AND DOSAGE; CELL LINE; CHEMISTRY; GENE TRANSFER; GENETICS; NEOPLASMS; OXIDATION REDUCTION REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE; CELL LINE, TUMOR; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; OLIGOPEPTIDES; OXIDATION-REDUCTION; PLASMIDS; POLYMERS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902553548     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.021     Document Type: Article

References (45)

1. Liu F., Huang L. Development of non-viral vectors for systemic gene delivery. JControl Release 2002, 78:259-266.
2. Wong S.Y., Pelet J.M., Putnam D. Polymer systems for gene delivery-past, present, and future. Prog Polym Sci 2007, 32:799-837.
3. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. Invitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
4. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2008, 109:259-302.
5. Lim Y.-B., Kim S.-M., Suh H., Park J.-S. Biodegradable, endosome disruptive, and cationic network-type polymer as a highly efficient and nontoxic gene delivery carrier. Bioconjug Chem 2002, 13:952-957.
6. Luten J., van Nostrum C.F., De Smedt S.C., Hennink W.E. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. JControl Release 2008, 126:97-110.
7. Ou M., Xu R., Kim S.H., Bull D.A., Kim S.W. Afamily of bioreducible poly (disulfide amine) s for gene delivery. Biomaterials 2009, 30:5804-5814.
8. Gosselin M.A., Guo W., Lee R.J. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug Chem 2001, 12:989-994.
9. Miyata K., Kakizawa Y., Nishiyama N., Harada A., Yamasaki Y., Koyama H., et al. Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression. JAm Chem Soc 2004, 126:2355-2361.
10. Kim H.J., Kwon M.S., Choi J.S., Yang S.-M., Yoon J.K., Kim K., et al. Highly effective and slow-biodegradable network-type cationic gene delivery polymer: small library-like approach synthesis and characterization. Biomaterials 2006, 27:2292-2301.
11. Kim T.-I., Kim S.W. Bioreducible polymers for gene delivery. React Funct Polym 2011, 71:344-349.
12. Ahn C.-H., Chae S.Y., Bae Y.H., Kim S.W. Biodegradable poly (ethylenimine) for plasmid DNA delivery. JControl Release 2002, 80:273-282.
13. Ou M., Wang X.-L., Xu R., Chang C.-W., Bull D.A., Kim S.W. Novel biodegradable poly (disulfide amine) s for gene delivery with high efficiency and low cytotoxicity. Bioconjug Chem 2008, 19:626-633.
14. Lin C., Zhong Z., Lok M.C., Jiang X., Hennink W.E., Feijen J., et al. Novel bioreducible poly (amido amine) s for highly efficient gene delivery. Bioconjug Chem 2007, 18:138-145.
15. Kim T.-I., Ou M., Lee M., Kim S.W. Arginine-grafted bioreducible poly (disulfide amine) for gene delivery systems. Biomaterials 2009, 30:658-664.
16. Lee Y., McGinn A.N., Olsen C.D., Nam K., Lee M., Shin S.K., et al. Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats. JControl Release 2013, 171:24-32.
17. Kim P.-H., Lee M., Kim S.W. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. JControl Release 2012, 162:9-18.
18. Kim P.-H., Kim J., Kim T.-i., Nam H.Y., Yockman J.W., Kim M., et al. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. Biomaterials 2011, 32:9328-9342.
19. Nam H.Y., Nam K., Lee M., Kim S.W., Bull D.A. Dendrimer type bio-reducible polymer for efficient gene delivery. JControl Release 2012, 160:592-600.
20. Kim H.A., Nam K., Lee M., Kim S.W. Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. JControl Release 2013, 171:1-10.
21. Won Y.-W., Lee M., Kim H.A., Nam K., Bull D.A., Kim S.W. Synergistically combined gene delivery for enhanced VEGF secretion and antiapoptosis. Mol Pharm 2013, 10:3676-3683.
22. Won Y.-W., McGinn A.N., Lee M., Nam K., Bull D.A., Kim S.W. Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia. Biomaterials 2013, 34:6229-6238.
23. Davis M.E., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
24. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
25. Prokop A., Davidson J.M. Nanovehicular intracellular delivery systems. JPharm Sci 2008, 97:3518-3590.
26. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
27. Danhier F., Breton A.L., Preat Vr RGD-based strategies to targetalpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol Pharm 2012, 9:2961-2973.
28. Park J., Singha K., Son S., Kim J., Namgung R., Yun C., et al. Areview of RGD-functionalized nonviral gene delivery vectors for cancer therapy. Cancer Gene Ther 2012, 19:741-748.
29. Chen W., Jarzyna P.A., van Tilborg G.A., Nguyen V.A., Cormode D.P., Klink A., et al. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 2010, 24:1689-1699.
30. Suh W., Han S.-O., Yu L., Kim S.W. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol Ther 2002, 6:664-672.
31. Kim W.J., Yockman J.W., Jeong J.H., Christensen L.V., Lee M., Kim Y.-H., et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. JControl Release 2006, 114:381-388.
32. Cai L.-L., Liu P., Li X., Huang X., Ye Y.-Q., Chen F.-Y., et al. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomed 2011, 6:3499-3508.
33. Jiang J., Yang S.-j., Wang J.-c., Yang L.-j., Xu Z.-z., Yang T., et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010, 76:170-178.
34. Kim J., Nam H.Y., Kim T.-i., Kim P.-H., Ryu J., Yun C.-O., et al. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials 2011, 32:5158-5166.
35. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. JCell Biol 1998, 141:1659-1673.
36. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
37. Leung D.W., Cachianes G., Kuang W.-J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
38. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth invivo. Nature 1993, 362:841-844.
39. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
40. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69:11-16.
41. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. Asmall interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-3370.
42. Juan H.F., Wang I., Huang T.C., Li J.J., Chen S.T., Huang H.C. Proteomics analysis of a novel compound: cyclic RGD in breast carcinoma cell line MCF-7. Proteomics 2006, 6:2991-3000.
43. Park T.G., Jeong J.H., Kim S.W. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006, 58:467-486.
44. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. JControl Release 2010, 145:182-195.
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. JImmunol Methods 1983, 65:55-63.